Newsroom
What's New With Genetesis.

Stay up-to-date with the latest Genetesis headlines, including product updates, research announcements, and more.

11 Jan 2022

Genetesis Announces New Appointments to Executive Leadership Team

Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux.
11 Jan 2022

Genetesis Founder Named Forbes 30 Under 30

Congratulations to co-founder, Peeyush Shrivastava alongside co-founders Manny Setegn and Vineet Erasala and other winners for making the Forbes Under 30 list for healthcare - 30 of the brightest young entrepreneurs saving lives and creating a more equitable future.
11 Jan 2022

Genetesis Announces Close of $17.5 Million Series C Financing

Mithril Capital-led Series C to launch 5-minute noninvasive ischemia assessment requiring no pharmaceuticals, no exercise, and no radiation.
11 Jan 2022

Genetesis Announces New Scientific Advisory Board 🧪

The group is comprised of world-class experts, researchers and thought leaders spanning cardiology, emergency medicine and radiology.
11 Jan 2022

Ms. Medicine and Genetesis Initiate WACE-MCG Clinical Registry ♀️

Ms.Medicine and Genetesis today announced the start of a clinical registry for Women’s Assessed Cardiovascular Evaluation with Magnetocardiography (WACE-MCG).
11 Jan 2022

CardioFlux Magnetocardiograph Case Studies 📋

Genetesis, the company behind CardioFlux, explain how Magnetic Field Maps (MFMs) are created and interpreted.
11 Jan 2022

Genetesis Applauds CMS’s MCIT Rule to Prove National Medicare Coverage For FDA Breakthrough Devices

Last month FDA designated Genetesis’ CardioFlux® as a Breakthrough Device for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.
11 Jan 2022

FDA awards Genetesis Breakthrough Device Designation for CardioFlux 🏆

CardioFlux®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.
11 Jan 2022

Genetesis Added Significant Strategic Investor- TDK Ventures

TDK Corporation (TSE: 6762) announces that subsidiary TDK Ventures Inc. adds to its growing portfolio of companies with an investment in Genetesis, a world leader in non-invasive biomagnetic imaging. (Photo: BusinessWire)
11 Jan 2022

Genetesis Brings Sajid Malhotra & Other Investors to Company

Genetesis has also added Sajid Malhotra to its Board of Directors. Malhotra brings extensive experience in senior executive positions in publicly traded companies.
11 Jan 2022

COVID-19 Further Overwhelms Chest Pain Triage Inefficiencies 😷

COVID-19 is causing a large rise in non-cardiac elevations of biomarkers, sometimes just due to general multiorgan fulminant inflammation, severely complicating the traditional methods to diagnose myocardial infarction.
11 Jan 2022

Magnetocardiography IDs Chest Pain in 90 Seconds ⌛

A 90-second chest scan could be a game-changer for triaging patients who present to the emergency department with undiagnosed chest pain, according to research out of Detroit.
11 Jan 2022

CardioFlux and Faraday Patient Experience

View the process from start to finish of a patient being scanned with the CardioFlux MCG.
11 Jan 2022

MedAxiom Announces Industry Partnership with Genetesis, Inc.

MedAxiom, the nation’s leading cardiovascular healthcare membership organization and performance community, is excited to announce its industry partnership with Genetesis, Inc.
11 Jan 2022

Genetesis Pilot Study: 90 Second Scan Shows Promise in Evaluating Chest Pain Patients

A new pilot study has found that a resting 90-second magnetocardiography (MCG) scan shows promise in evaluating emergency department observation unit (EDOU) chest pain patients for Acute Coronary Artery Syndrome.
11 Jan 2022

WVU Heart and Vascular Institute Innovations Aim to Deal with Heart Disease, Imaging

Work at WVU Medicine to use new technology to treat cardiac issues is gaining national attention and offering new options to patients.
11 Jan 2022

‘Shark Tank’ Billionaire Mark Cuban Adds to Investment in Cincinnati Firm

CincyTech and the Ohio Innovation Fund led the round, which included significant investments from TDK Ventures and an undisclosed global health care company that ranks in the Fortune 500. (Image: Getty. Illustration: Chloe Krammel)
11 Jan 2022

Genetesis Lands Strategic Investment to Close Series B

The company has closed significant strategic investments from TDK Ventures and an undisclosed Fortune 500 global, healthcare company, completing a $9.2M Series B financing. 💵
11 Jan 2022

Magneto-Electrocardiogram - Dr. Partho Sengupta, WVU Medicine

Doctors at the WVU Heart and Vascular Institute are in clinical trials of a new technology that could make current methods of detecting heart disease obsolete. (Photo: TEDMED)
11 Jan 2022

Cincy Inno’s 2019 Coolest Companies 🕶️

We asked you, the Cincinnati startup and entrepreneurial community, for input on which in-state companies were the ✨coolest✨— and you answered our call. Together, with editorial insight, we developed a list of entities whose culture stands out.
11 Jan 2022

Cincinnati Medical Device Startup Wins Statewide Award

A Cincinnati medical device startup won a statewide award from VentureOhio, a group devoted to boosting the Buckeye State's entrepreneurial ecosystem, marking the second year in a row it has been honored by the organization.
11 Jan 2022

5 Startups Mark Cuban Thinks Will Shape the Future 🧠 🚀

Some of the most intriguing businesses the billionaire has backed didn't appear on 'Shark Tank.' (Photo: KCM/Getty)
11 Jan 2022

$7.5 million Series A Funding Closed

Genetesis, a medical device company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, has closed an oversubscribed round of $7.5M in Series A financing.